Immunosuppressants & ARVs

Drug-drug interactions between Immunosuppresants (for SOT) & ARVs

  Potential increased exposure of the immunosuppressant
  Potential decreased exposure of the immunosuppressant
No significant effect
D  Potential decreased exposure of ARV drug
E  Potential elevated exposure of ARV drug

ATV/c    ATV co-formulated with COBI (300/150 mg qd);
DRV/c    DRV co-formulated with COBI (800/150 mg qd)

* available as prolonged release formulation

Numbers refer to decreased/increased AUC as observed in drug-drug interaction studies. 

AM = antimetabolite
CNI = calcineurin inhibitors   
CS  = corticosteroids   
mTOR =  mTOR inhibitors

Interactions with ZDV
Azathioprine (potential risk of additive hematotoxicity).
Mycophenolate (potential alteration in mycophenolate level, monitor plasma concentrations)


  1. TDM of immunosuppressant is recommended
  2. Monitor renal function

Further Information    
For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to (University of Liverpool).